Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TJX Companies Inc (TJX) vs Twist Bioscience Corp (TWST) Price & Performance

TJX Companies IncTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

TJX Companies Inc vs Twist Bioscience Corp — how do they compare? TJX Companies Inc trades at $152.89 (market cap $172.05B), while Twist Bioscience Corp trades at $124.3 (market cap $7.72B). The key difference: TJX Companies Inc is far larger — about 22.3× Twist Bioscience Corp's market cap, and TJX Companies Inc pays a 1.23% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

TJXTWST
Market Cap
$172.05B$7.72B
Sector
Consumer CyclicalHealth
52-Week High
$168.41$124.88
52-Week Low
$132.62$24.16
Enterprise Value
$180.65B$7.65B
Dividend Yield
1.23%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

TJX Companies Inc

TJX trades at $152.64, down 3.88% in the last session, with a bearish technical signal but strong fundamentals including a 61.25% ROE and consistent earnings beats. Revenue grew to $56.36B in 2025, with net income margin expanding to 8.63%. The company maintains robust cash flow from operations at $6.12B and announced dividends of $0.48 per share for H1 and H2 2026.

Outlook remains positive with analyst consensus price target of $181.80 (19% upside), supported by 88% buy ratings. Risks include competitive discount retail pressures and macroeconomic sensitivity, but TJX's value proposition and growth trajectory offer investment opportunity pending Q2 2026 earnings on August 19, 2026.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.

The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.

Returns comparison

Trailing returns across standard periods

About TJX Companies Inc

TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.

Read more on TJX

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST